Stereotactic body radiation therapy for primary kidney cancer

L. Abancourt; J. Le Guévelou; A. Taillez; A. Vu; R. de Crevoisier; S. Supiot; C. Hennequin; O. Chapet; P. Blanchard; X. Mirabel; Lartigau; D. Pasquier

doi:10.1016/j.canrad.2023.06.022

Stereotactic body radiation therapy for primary kidney cancer

Titre traduit de la contribution: Radiothérapie stéréotaxique des carcinomes rénaux primitifs

L. Abancourt, J. Le Guévelou, A. Taillez, A. Vu, R. de Crevoisier, S. Supiot, C. Hennequin, O. Chapet, P. Blanchard, X. Mirabel, Lartigau, D. Pasquier

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

Résumé

The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40 Gy in five fractions, 42 Gy in three fractions, and 26 Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary.

Titre traduit de la contribution	Radiothérapie stéréotaxique des carcinomes rénaux primitifs
langue originale	Anglais
Pages (de - à)	568-572
Nombre de pages	5
journal	Cancer/Radiotherapie
Volume	27
Numéro de publication	6-7
Les DOIs	https://doi.org/10.1016/j.canrad.2023.06.022
état	Publié - 1 sept. 2023

Accès au document

10.1016/j.canrad.2023.06.022

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{909164fd2c97432383deb29a59f0ba35,

title = "Stereotactic body radiation therapy for primary kidney cancer",

abstract = "The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40 Gy in five fractions, 42 Gy in three fractions, and 26 Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary.",

keywords = "Primary kidney cancer, Renal cell carcinoma, Stereotactic body radiotherapy",

author = "L. Abancourt and {Le Gu{\'e}velou}, J. and A. Taillez and A. Vu and {de Crevoisier}, R. and S. Supiot and C. Hennequin and O. Chapet and P. Blanchard and X. Mirabel and Lartigau and D. Pasquier",

note = "Publisher Copyright: {\textcopyright} 2023 Soci{\'e}t{\'e} fran{\c c}aise de radioth{\'e}rapie oncologique (SFRO)",

year = "2023",

month = sep,

day = "1",

doi = "10.1016/j.canrad.2023.06.022",

language = "English",

volume = "27",

pages = "568--572",

journal = "Cancer/Radiotherapie",

issn = "1278-3218",

number = "6-7",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for primary kidney cancer

AU - Abancourt, L.

AU - Le Guévelou, J.

AU - Taillez, A.

AU - Vu, A.

AU - de Crevoisier, R.

AU - Supiot, S.

AU - Hennequin, C.

AU - Chapet, O.

AU - Blanchard, P.

AU - Mirabel, X.

AU - Lartigau,

AU - Pasquier, D.

PY - 2023/9/1

Y1 - 2023/9/1

N2 - The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40 Gy in five fractions, 42 Gy in three fractions, and 26 Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary.

AB - The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40 Gy in five fractions, 42 Gy in three fractions, and 26 Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary.

KW - Primary kidney cancer

KW - Renal cell carcinoma

KW - Stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85167802218&partnerID=8YFLogxK

U2 - 10.1016/j.canrad.2023.06.022

DO - 10.1016/j.canrad.2023.06.022

M3 - Review article

C2 - 37543493

AN - SCOPUS:85167802218

SN - 1278-3218

VL - 27

SP - 568

EP - 572

JO - Cancer/Radiotherapie

JF - Cancer/Radiotherapie

IS - 6-7

ER -